Envafolimab
Envafolimab (ASC 22; KN 035) is a recombinant protein of a humanized single-domain anti- PD-L1 antibody. Envafolimab is created by a fusion of the of anti-PD-L1 domain with Fc fragment of human IgG1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25 nM. Envafolimab has the potential for the research of solid tumors[1][2][3].
Product Specifications
CAS Number
2102192-68-5
Product Name Alternative
ASC 22; KN 035
UNSPSC
12352203
Target
PD-1/PD-L1
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/envafolimab.html
Purity
99.77
Solubility
H2O
Smiles
[Envafolimab]
Molecular Weight
(80 kDa)
References & Citations
[1]Papadopoulos KP, et al. First-in-Human Phase I Study of Envafolimab, a Novel Subcutaneous Single-Domain Anti-PD-L1 Antibody, in Patients with Advanced Solid Tumors. Oncologist. 2021 Sep;26 (9) :e1514-e1525.|[2]Akinleye A, et al. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 2019 Sep 5;12 (1) :92.|[3]Zhang F, Wei H, Wang X, Bai Y, Wang P, Wu J, Jiang X, Wang Y, Cai H, Xu T, Zhou A. Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade. Cell Discov. 2017 Mar 7;3:17004.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
abx461773-01 100 µg
Clostridium botulinum Neurotoxin Type A (botA) Antibody
Sign In for Pricing
View Details abx461773-02 1 mg
Clostridium botulinum Neurotoxin Type A (botA) Antibody
Sign In for Pricing
View Details K3921402 1.0 µg DNA
Cdk2ap1 sgRNA CRISPR Lentivector (Mouse) (Target 1)
Sign In for Pricing
View Details 
K6150603 1.0 µg DNA
Fbxo33 sgRNA CRISPR Lentivector (Rat) (Target 2)
Sign In for Pricing
View Details 